Cargando…

Efficient Delivery of DNA Vaccines using Human Papillomavirus Pseudovirions

We have examined non-replicative human papillomavirus (HPV) pseudovirions as an approach in the delivery of naked DNA vaccines without safety concerns associated with live viral vectors. In the current study, we have generated HPV-16 pseudovirions encapsidating a DNA vaccine encoding the model antig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Shiwen, Monie, Archana, Kang, Tae Heung, Hung, Chien-Fu, Roden, Richard, Wu, T.-C.
Formato:	Texto
Lenguaje:	English
Publicado:	2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972366/ https://www.ncbi.nlm.nih.gov/pubmed/20668481 http://dx.doi.org/10.1038/gt.2010.106

Ejemplares similares

DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity
por: Peng, Shiwen, et al.
Publicado: (2011)

Ovarian Cancer Gene Therapy Using HPV-16 Pseudovirion Carrying the HSV-tk Gene
por: Hung, Chien-Fu, et al.
Publicado: (2012)

Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells
por: Lamprecht, Renate L, et al.
Publicado: (2016)

Innovative DNA Vaccine for Human Papillomavirus (HPV)-Associated Head and Neck Cancer
por: Wu, Annie, et al.
Publicado: (2010)

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
por: Peng, Shiwen, et al.
Publicado: (2011)

Novel Production of Bovine Papillomavirus Pseudovirions in Tobacco Plants
por: Pietersen, Inge, et al.
Publicado: (2020)

In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination
por: Mao, Chih-Ping, et al.
Publicado: (2011)

Enhancing DNA vaccine potency by co-administration of xenogenic MHC-class-I DNA
por: Kang, Tae Heung, et al.
Publicado: (2009)

Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination
por: Yang, Benjamin, et al.
Publicado: (2015)

Cervarix(™): a vaccine for the prevention of HPV 16, 18-associated cervical cancer
por: Monie, Archana, et al.
Publicado: (2008)

Vimentin Modulates Infectious Internalization of Human Papillomavirus 16 Pseudovirions
por: Schäfer, Georgia, et al.
Publicado: (2017)

Measurement of Neutralizing Serum Antibodies of Patients Vaccinated with Human Papillomavirus L1 or L2-Based Immunogens Using Furin-Cleaved HPV Pseudovirions
por: Wang, Joshua W., et al.
Publicado: (2014)

Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies
por: Combelas, Nicolas, et al.
Publicado: (2010)

Autophagy is induced in human keratinocytes during human papillomavirus 11 pseudovirion entry
por: Han, Rui, et al.
Publicado: (2020)

High-Throughput Pseudovirion-Based Neutralization Assay for Analysis of Natural and Vaccine-Induced Antibodies against Human Papillomaviruses
por: Sehr, Peter, et al.
Publicado: (2013)

Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method
por: Toh, Zheng Quan, et al.
Publicado: (2020)

Immunologic Control of Mus musculus Papillomavirus Type 1
por: Wang, Joshua W., et al.
Publicado: (2015)

Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
por: Chuang, Chi-Mu, et al.
Publicado: (2010)

Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects
por: Chuang, Chi-Mu, et al.
Publicado: (2009)

Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease
por: Peng, Shiwen, et al.
Publicado: (2016)

Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus
por: Nie, Jianhui, et al.
Publicado: (2016)

Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection
por: Jiang, Rosie T., et al.
Publicado: (2017)

Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody
por: Peng, Shiwen, et al.
Publicado: (2021)

Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus
por: Yang, Andrew, et al.
Publicado: (2017)

Inhibition of Multidrug Resistance by SV40 Pseudovirion Delivery of an Antigene Peptide Nucleic Acid (PNA) in Cultured Cells
por: Macadangdang, Benjamin, et al.
Publicado: (2011)

Immunogenicity correlation in cynomolgus monkeys between Luminex‐based total IgG immunoassay and pseudovirion‐based neutralization assay for a 14‐valent recombinant human papillomavirus vaccine
por: Bei, Lei, et al.
Publicado: (2022)

Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation
por: Wu, Chao-Yi, et al.
Publicado: (2010)

Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination
por: Tseng, Chih-Wen, et al.
Publicado: (2008)

Thiol-reactive reagents inhibits intracellular trafficking of human papillomavirus type 16 pseudovirions by binding to cysteine residues of major capsid protein L1
por: Ishii, Yoshiyuki, et al.
Publicado: (2007)

Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells
por: Peng, Shiwen, et al.
Publicado: (2014)

Multivalent Human Papillomavirus L1 DNA Vaccination Utilizing Electroporation
por: Kwak, Kihyuck, et al.
Publicado: (2013)

Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors
por: Kim, Daejin, et al.
Publicado: (2010)

Depletion of platelets enhances therapeutic antitumor effects generated by therapeutic DNA vaccine
por: Lee, Sung Yong, et al.
Publicado: (2013)

Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation
por: Sun, Yunyan, et al.
Publicado: (2017)

Mechanisms regulating expression of the HPV 31 L1 and L2 capsid proteins and pseudovirion entry
por: Hindmarsh, Patrick L, et al.
Publicado: (2007)

Inhibitors of SARS-CoV entry – Identification using an internally-controlled dual envelope pseudovirion assay
por: Zhou, Yanchen, et al.
Publicado: (2011)

Optimization of SARS-CoV-2 Pseudovirion Production in Lentivirus Backbone With a Novel Liposomal System
por: Mahalingam, Gokulnath, et al.
Publicado: (2022)

Optimization of Multimeric Human Papillomavirus L2 Vaccines
por: Jagu, Subhashini, et al.
Publicado: (2013)

Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs
por: Hetrick, Brian, et al.
Publicado: (2022)

Cytoplasmic Tail Truncation Stabilizes S1-S2 Association and Enhances S Protein Incorporation into SARS-CoV-2 Pseudovirions
por: Zhang, Lizhou, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8uavg9j8fhhc0t3glarmupo74t